Tech Company Financing Transactions
Bambusa Therapeutics Funding Round
On 9/9/2024, Bambusa Therapeutics announced $15 million in Seed funding from BVF Partners, Dawn Biopharma and INCE Capital.
Transaction Overview
Company Name
Announced On
9/9/2024
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of its pipeline of bispecific antibodies to Phase I clinical studies.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shanshan Xu
Co-Founder
Helmut Jeggle
Browse more venture capital transactions:
Prev: 9/9/2024: Mangomint venture capital transaction
Next: 9/9/2024: CardiaTec venture capital transaction
Share this article
Where The Data Comes From
We document tech company VC transactions. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs